J&J Full Steam Ahead On Separating Consumer Business While Inflation, Pandemic Slow Results
Executive Summary
While target date for spinning out consumer business into publicly traded company remains some time in 2023, J&J includes additional details on separation timetable with its 2021 full-year and fourth-quarter results.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Pivoting From Planning Changes To Parsing Results
Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.
‘Increasingly Challenging’ Environment Shifted J&J's Plans Toward Consumer Business Separation
Pharma R&D VP Mathai Mammen acknowledges “pros and cons to remaining” as one company but dismissed “any meaningful downside” for the pharma business, which along with the device business will continue operating as J&J.
France’s Mayoly Spindler Set To Acquire Ipsen’s Consumer Business
Mayoly Spindler is stepping up its presence in the self-care market with the acquisition of Ipsen's Consumer Healthcare business, which has been under strategic review for the past year.